Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 19/20 | 0.73 |
| ▸ | THRB | P10828 | 19/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.73 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.73 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.73 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.73 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24032592 | 0.86 | THRA (0.81) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL23441631 | 0.85 | THRA (0.80) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL23420796 | 0.84 | THRA (0.78) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL13907340 | 0.84 | THRB (1.00) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL22743670 | 0.83 | THRA (0.77) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL22743700 | 0.83 | THRA (0.77) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL22632618 | 0.83 | THRA (1.00) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL22632837 | 0.83 | THRA (0.75) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL23442447 | 0.83 | THRA (0.75) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL24032559 | 0.83 | THRA (0.84) | THRATHRBCYP2C9UGT1A1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113454069-B | 1,2, 4-Triazine-3, 5-dione compound, and preparation method and application thereof | 昆药集团股份有限公司 | 2025-03-14 | — | — | CN | disclosed |
| EP-4083024-A1 | 1,2,4-TRIAZINE-3,5-DIONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | KPC Pharmaceuticals, Inc. (CN) | 2022-11-02 | — | — | EP | disclosed |
| US-20210355110-A1 | THYROID HORMONE RECEPTOR AGONISTS | InventisBio Co., Ltd. (CN) | 2021-11-18 | — | — | US | disclosed |
| WO-2021104288-A1 | 1,2,4-TRIAZINE-3,5-DIONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 昆药集团股份有限公司 | 2021-06-03 | — | — | WO | disclosed |
| WO-2021104288-A1 | 1,2,4-TRIAZINE-3,5-DIONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 昆药集团股份有限公司 | 2021-06-03 | — | — | WO | disclosed |
| US-20210115022-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115022-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF | TSHR, THRA, TRHR | THRA 2/4885THRB 4/4885CYP2C9 2934/4885 |
| US-20210355110-A1 | THYROID HORMONE RECEPTOR AGONISTS | TSHR, THRA, TRHR | THRA 2/4885THRB 4/4885CYP2C9 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.